A Gene Therapy Study for Hemophilia B

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 18, 2015

Primary Completion Date

April 8, 2019

Study Completion Date

April 8, 2019

Conditions
Hemophilia B
Interventions
BIOLOGICAL

SPK-9001

A novel, bioengineered adeno-associated viral vector carrying human factor IX variant

Trial Locations (10)

2050

Royal Prince Alfred Hospital, Camperdown/Sydney

10065

Weill Cornell Medicine - New York Presbyterian Hospital, New York

19104

The Children's Hospital of Philadelphia, Philadelphia

39110

Mississippi Center for Advanced Medicine, Madison

39216

University of Mississippi Medical Center, Jackson

95817

UC Davis Comprehensive Cancer Center, Sacramento

UC Davis CTSC Clinical Research Center, Sacramento

UC Davis Ellison Ambulatory Care Clinic, Sacramento

UC Davis Investigational Pharmacy, Sacramento

UC Davis Medical Center, Sacramento

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY